ISPOR - FDA Orphan Exploitation? Are Pharma’s Approaches to Orphan Oncology Drug Approval Fuelling a Push for Reform By the FDA?

Full Text

FDA Orphan Exploitation? Are Pharma’s Approaches to Orphan Oncology Drug Approval Fuelling a Push for Reform By the FDA?

Abstract

Authors

R Macaulay B Cieply GD Wang

Back to Volume 21, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now